WO2003011296A1 - Pharmaceutical preparations containing aminobenzene- sulfonic acid derivatives as the active ingredient - Google Patents
Pharmaceutical preparations containing aminobenzene- sulfonic acid derivatives as the active ingredient Download PDFInfo
- Publication number
- WO2003011296A1 WO2003011296A1 PCT/JP2002/007656 JP0207656W WO03011296A1 WO 2003011296 A1 WO2003011296 A1 WO 2003011296A1 JP 0207656 W JP0207656 W JP 0207656W WO 03011296 A1 WO03011296 A1 WO 03011296A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- coating layer
- pharmaceutical preparation
- active ingredient
- acid
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 36
- 239000004480 active ingredient Substances 0.000 title claims abstract description 27
- ZMCHBSMFKQYNKA-UHFFFAOYSA-N 2-aminobenzenesulfonic acid Chemical class NC1=CC=CC=C1S(O)(=O)=O ZMCHBSMFKQYNKA-UHFFFAOYSA-N 0.000 title claims abstract description 13
- 239000011247 coating layer Substances 0.000 claims abstract description 49
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims abstract description 45
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000000126 substance Substances 0.000 claims abstract description 32
- 230000014759 maintenance of location Effects 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 10
- 239000012453 solvate Substances 0.000 claims abstract description 8
- 239000011248 coating agent Substances 0.000 claims description 40
- 238000000576 coating method Methods 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 38
- 238000009472 formulation Methods 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- -1 ^ —C 6 alkyl group Chemical group 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 239000010410 layer Substances 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 claims description 7
- OMOVVBIIQSXZSZ-UHFFFAOYSA-N [6-(4-acetyloxy-5,9a-dimethyl-2,7-dioxo-4,5a,6,9-tetrahydro-3h-pyrano[3,4-b]oxepin-5-yl)-5-formyloxy-3-(furan-3-yl)-3a-methyl-7-methylidene-1a,2,3,4,5,6-hexahydroindeno[1,7a-b]oxiren-4-yl] 2-hydroxy-3-methylpentanoate Chemical compound CC12C(OC(=O)C(O)C(C)CC)C(OC=O)C(C3(C)C(CC(=O)OC4(C)COC(=O)CC43)OC(C)=O)C(=C)C32OC3CC1C=1C=COC=1 OMOVVBIIQSXZSZ-UHFFFAOYSA-N 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 5
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 5
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 2
- MVIOINXPSFUJEN-UHFFFAOYSA-N benzenesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)C1=CC=CC=C1 MVIOINXPSFUJEN-UHFFFAOYSA-N 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 238000004811 liquid chromatography Methods 0.000 abstract 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- ZAJAQTYSTDTMCU-UHFFFAOYSA-N 3-aminobenzenesulfonic acid Chemical compound NC1=CC=CC(S(O)(=O)=O)=C1 ZAJAQTYSTDTMCU-UHFFFAOYSA-N 0.000 description 2
- 101150085479 CHS2 gene Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 241000269799 Perca fluviatilis Species 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001782 photodegradation Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- ZRQKZWAOIRVBFD-UHFFFAOYSA-N 5-methyl-2-piperazin-1-ylbenzenesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)C1=CC(C)=CC=C1N1CCNCC1 ZRQKZWAOIRVBFD-UHFFFAOYSA-N 0.000 description 1
- FLHUBXQONHAIJW-UHFFFAOYSA-N 5-phenyl-2-piperazin-1-ylbenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC(C=2C=CC=CC=2)=CC=C1N1CCNCC1 FLHUBXQONHAIJW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical class C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- XDLDASNSMGOEMX-UHFFFAOYSA-N benzene benzene Chemical class C1=CC=CC=C1.C1=CC=CC=C1 XDLDASNSMGOEMX-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000005921 isopentoxy group Chemical group 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005922 tert-pentoxy group Chemical group 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
Definitions
- the present invention relates to a pharmaceutical preparation coated with a coating to prevent the generation of a photolytic substance.
- light-shielding methods for preventing the photodegradation of pharmaceutical preparations, such as using a light-shielding coating that shields the pharmaceutical park itself, a light-shielding PTP package that shields light from the packaging, a front aluminum package, and light-shielding paper.
- a light-shielding coating that shields the pharmaceutical park itself
- a light-shielding PTP package that shields light from the packaging
- a front aluminum package and light-shielding paper.
- the method of shielding light from the packaging cannot guarantee the stability after opening the package, and therefore, it is considered desirable to shield the formulation PAR itself from light.
- titanium oxide is generally used as a light-shielding component, and various formulations are known.
- an object of the present invention is to provide a stable drug of the above-mentioned aminobenzenesulfonic acid derivative. Disclosure of the invention
- the present inventors have conducted intensive studies to solve the above problems, and as a result, first applied a coating without titanium oxide to the above-mentioned unmodified benzenebenzene derivative, followed by a coating containing titanium oxide.
- a coating containing titanium oxide To provide a tablet that is degraded by the reaction of aminobenzenesulfonic acid and light as a drug substance, and a tablet that prevents the formation of aminobenzenesulfonic acid, titanium oxide and a degraded product due to light as a drug substance.
- a tablet that is degraded by the reaction of aminobenzenesulfonic acid and light as a drug substance and a tablet that prevents the formation of aminobenzenesulfonic acid, titanium oxide and a degraded product due to light as a drug substance.
- R 2 is selected from the group consisting of a hydrogen atom, an alkyl group of Ci—Cs, or a cyano group, a nitro group, an alkoxy group of c_c 6 , a halogen atom, an alkyl group of c 6 , and an amino group 1 Or a C 7 -C 12 aralkyl group which may have two or more substituents; n represents an integer of 1 to 4.
- a pharmaceutical preparation comprising, as an active ingredient, an aminobenzenesulfonic acid derivative represented by the formula (I) or a salt thereof, or a hydrate or solvate thereof, wherein the pharmaceutical preparation is sodium dihydrogen phosphate dihydrate 8 mol of a solution prepared by dissolving 7.8 g of the product in 1,000 mL of water / acetonitrile mixture (6: 1) / L sodium hydroxide solution and extract with diluent adjusted to pH 7.0, UV spectrophotometer 220 nm, octylsilylated silica gel packed column (4 mm X 250 mm), 40 ° C, using a mobile phase in which 7.8 g of sodium dihydrogen phosphate dihydrate was dissolved in 100 mL of water / acetonitrile (6: 1), the retention time of the active ingredient was about 7
- the substance A has a retention time of about 6.4 minutes on high performance liquid chromatography, which elutes at a flow rate adjusted to be 1 minute
- the pharmaceutical preparation is characterized in that the coating layer comprises two layers; a first coating layer for the coating layer to substantially suppress the generation of the substance A;
- the pharmaceutical preparation which comprises a second coating layer for substantially suppressing the production of the substance B and the substance C; wherein the first coating layer does not contain titanium oxide.
- the pharmaceutical preparation wherein the second coating layer comprises titanium oxide; the pharmaceutical preparation being a tablet; and, for an uncoated tablet, a first coating layer; Coating layer.
- C 12 R 2 is a hydrogen atom, Ci Cg alk Or one or more substituents selected from the group consisting of a cyano group, a cyano group, a nitro group, a C i-C s alkoxy group, a no, a gen atom, a ⁇ -C s alkyl group, and an amino group.
- the first coating layer does not contain titanium oxide; the second coating layer contains titanium oxide; and, for an uncoated tablet, the first coating layer, As a preferred embodiment, it is preferred to be coated with a coating layer.
- the active ingredient of the pharmaceutical preparation of the present invention includes the aminobenzenesulfonic acid derivative represented by the above general formula (I) or a salt thereof, or a hydrate or a solvate thereof.
- the above general formula (I) it is defined by i —
- the C 6 alkyl group include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, and a tert-butyl group.
- C 3 -C 7 cycloalkyl groups include cyclopropyl group, And a chlorobutinole group, a cyclopentynole group, a cyclohexynole group, a cycloheptinol group and the like.
- Examples of the C 4 halogenated alkyl group include a trifluoromethyl group, a trifluoroethyl group, and a pentafluoroethyl group.
- halogen atom examples include a fluorine atom, a chlorine atom, and a bromine atom.
- aryl group of c 6 —c 12 examples include a phenyl group and a naphthyl group.
- Preferred examples include a hydrogen atom, an alkyl group of Ci—C 6, a cycloalkyl group of C 5 —C 6, a trifluoromethyl group, a halogen atom or a phenyl group, and more preferred examples include C—C And alkyl, cyclohexyl, trifluoromethyl, chlorine, bromine and phenyl groups, and particularly preferably a methyl group or a propyl group.
- the C—C 6 alkyl group defined for R 2 includes, for example, the alkyl groups defined above.
- Examples of the aralkyl group of c 7 to c 12 include a benzyl group, a phenethyl group, a naphthylmethyl group and the like.
- the aralkyl group is a cyano group; a nitro group; a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, an isobutoxy group, a tert-butoxy group, a pentyloxy group, an isopentyloxy group, and a tert-pentyloxy group.
- a hexyloxy group or the like a C 6 alkoxy group; a halogen atom as defined above; and one or more substituents selected from the group consisting of an alkyl group and an amino group as defined above. It may be.
- R 2 include a hydrogen atom, a C 3 alkyl group, and a C 1 -Cg alkyl group, a C 1 -C 3 alkoxy group and one or more substituents selected from halogen atoms.
- a C 7 _C 12 aralkyl group which may be further preferred is, for example, R 2 is a hydrogen atom or A C 7 -C 12 aralkyl group which may have one or more substituents selected from —C 3 alkoxy groups; and particularly preferably a hydrogen atom.
- n is preferably 2.
- Preferred specific examples of the present invention include the compounds shown in Tables 1 and 2 below.
- a compound in which the substitution position of at the 5-position is preferable, and more preferable compounds include the following compounds.
- 5_n-propyl-1- (1-piperazinole) benzenesulfonic acid 5-phenyl-2- (1-piperazinyl) benzenesulfonic acid; 5-chloro-1- (1-piperazininole) benzenesnolephonic acid; 5 —Bromo-2- (1 piperazinole) benzenesnolephonic acid; 5—iso-propyl-1- (1-piperazinole) benzenesnolefonic acid; 5-cyclohexinole-2- (1-piperazinole) benzenesnolefonic acid;
- particularly preferred examples include 5-methyl-2- (1-piperazinole) benzenesnolephonic acid and 5-n-propyl-12- (1-piperazul) benzenesulfonic acid. .
- salts of the above compounds include, for example, sodium salts, potassium salts, magnesium salts, calcium salts, aluminum salts and other alkaline metal salts or alkaline earth metal salts; ammonium salts, triethylamine salts Lower alkylamine salts, such as 2-hydroxyhydrylamine salts, bis- (2-hydroxylethyl) amine salts, tris (hydroxymethyl) minomethane salts, N-methyl-D-glucamine salts, etc.
- Alkylamine salts such as alkylamine salts and dihexylhexylamine salts; amine salts such as penzinoleamine salts such as N, N-dibenzinoleethylenediamine salts and dibenzylamine salts; hydrochlorides, hydrobromides; Inorganic salts such as sulfates and phosphates; and organic acid salts such as fumarate, succinate, oxalate, and lactate It is.
- any hydrate or solvate thereof may be used as an active ingredient of the medicament of the present invention, in addition to a salt or a compound in a free form.
- Solvents capable of forming a solvate of the above compound include, for example, methanol, ethanol, Examples include isopropyl alcohol, acetone, ethyl acetate, and methylene chloride.
- the most preferred active ingredient of the present invention is 5-methyl-2- (1-piperazinyl) benzenesulfonic acid monohydrate.
- the amino benzene sulfonic acid derivative represented by the above general formula (I) is a known compound.
- Japanese Patent Application Laid-Open Nos. 3-7263 and 9-2221479 each discloses a compound.
- a tablet will be described as a typical example of the pharmaceutical preparation of the present invention, but the present invention is not limited to a tablet unless it exceeds the gist of the present invention.
- the active ingredient i.e. c using conventional formulation techniques, by mixing the compound with an excipient, granulating if necessary, sieved, tableting a mixture of smooth Sawazai I do.
- Excipients include lactose, mannitol, corn starch, potato starch, crystalline cellulose, and the like.
- Binders for granulation include hydroxypropyl cellulose, polyvinyl alcohol, povidone, etc.
- Lubricants include magnesium stearate, calcium stearate, stearate, etc.
- Disintegrators include sodium carboxymethyl starch, cros-canolemelose sodium, carmellose calcium, crospovidone, etc.
- Flow improvers include hydrous silicon dioxide, light silicic anhydride and the like.
- the amounts of these additives are determined in consideration of the formulation design, the stability of the formulation, and the scalability of the production.
- an ordinary perch cardinal drier is used.
- a normal granulation method may be used as the granulation method, and examples thereof include a fluidized bed granulation method and a stirring granulation method.
- a fluidized bed granulator, a perch carder and the like are used respectively.
- mixing lubricants use a V-type mixer or the like.
- For tableting use an ordinary tableting machine.
- the coating layer is preferably composed of two layers.
- the formation of the substance A is substantially suppressed by the first coating layer, and the formation of the substances B and C is substantially suppressed by the second coating layer. It is preferable to use a method that suppresses the damage.
- the first coating layer is not particularly limited as long as it is a formulation that substantially suppresses the generation of the substance A.
- An example of the first coating layer is a coating layer containing no titanium oxide. As long as it does not contain titanium oxide, other formulations are not particularly limited. That is, In one coating layer, any formulation may be used as long as the formation of the substance A, which is a substance generated by the reaction of the active ingredient with titanium oxide and light, is substantially suppressed.
- the second coating layer is not particularly limited as long as it is a formulation that substantially suppresses the production of the substances B and C.
- An example thereof is a coating layer containing titanium oxide. .
- the formulation may be such that the production of the substance B and the substance C, which are substances produced by the reaction with the active ingredient and light, is substantially suppressed.
- the first coating layer has The formulation may be such that the formation of a substance produced by the reaction between the active ingredient and the light-shielding agent and light used is substantially suppressed.
- the main ingredient of the coating formulation is a coating base.
- the coating base include hydroxypropyl methylcellulose.
- a plasticizer or a light-blocking agent may be added.
- the plasticizer include macrogol and propylene glycol.
- the light-shielding agent include titanium oxide and other light-shielding agents commonly used in the production of pharmaceuticals. In the present invention, the preferred light-shielding agent is titanium oxide.
- composition ratios need to be sufficient to achieve the purpose of adding the individual components.
- these coating components are It is dissolved or suspended in an organic solvent and sprayed on uncoated tablets as a coating solution.
- the solid content concentration of the coating liquid depends on the characteristics and operating conditions of the coating equipment and the quality of the target coating, but may be, for example, 1 to 50%, preferably 10 to 15%.
- the amount of coating per uncoated tablet must be sufficient to achieve the purpose of suppressing the generation of degraded products of this compound, and the active ingredient content, weight, size, and shape of the complaint are required. It depends on the condition. For example, for uncoated tablets with a weight of 135 mg and a size of 7 mm ⁇ 9 R containing 0.2 mg of the active ingredient, the formation of degraded products due to “this compound + titanium oxide + light” is suppressed.
- the agents of the present invention are formed into tablets.
- the dose of the drug of the present invention may be appropriately determined in consideration of the purpose of treatment or prevention, the type of disease to be treated or prevented, the patient's symptoms, weight, age, gender, and the like.
- O. Olmg ⁇ : LOOOmg can be administered by daily dosing. It is desirable to administer such dosage in 1 to several times a day.
- composition 0.2 mg of active ingredient, appropriate amount of mannitol, corn starch 23.0 mg, low-substituted hydroxypropyl cellulose 6.8 mg, hydroxypropylcellulose 10 .1 mg, magnesium stearate 2 Mixing, granulation, lubricating agent mixing, and tableting were performed in the usual manner so that the total amount of 7 mg and uncoated tablets totaled 135 mg to obtain uncoated tablets with a tablet diameter of 7 mm (Prescription 1). .
- the tablets of Formula 1 and Formula 2 are irradiated with light of 600,000 LuX ⁇ hr and 120,000 Lux ⁇ hr using an optical tester, and are related by high performance liquid mouth chromatography (HP LC).
- HP LC high performance liquid mouth chromatography
- An analogous test was conducted by dissolving 7.8 g of the above-obtained tablets in 1 000 mL of a mixture of water and nitronitrile (6: 1) at a concentration of 8 mol / L. Extraction was performed with a diluent adjusted to pH 7.0 by adding a sodium solution, followed by HP LC analysis and comparison with a standard product. The preparation of the sample solution was performed in a dark room.
- the conditions of HP LC are as follows.
- the uncoated tablet of Formulation 1 obtained in Example 1 above was coated so as to have a total of 5.0 mg of hydroxypropylmethyl senorellose 3.8 mg, propylene glycol cornole 0.7 mg, tanolek 0.5 mg.
- a coated tablet (formulation 3) without titanium oxide was obtained.
- 3.l mg of hydroxypropyl methinorecellulose, 0.6 mg of propylene dalicol, titanium oxide (A-100, hereinafter sometimes referred to as “titanium oxide B”) 0 9 mg, 0.4 mg of talc, and a total of 5.0 mg were coated to obtain a coated tablet containing titanium oxide B (formulation 4).
- the tablets of Formulations 1 to 5 were irradiated with light of 300,000 Lux ⁇ hr using an optical tester, and an analog test was performed using HPLC. The analog test was performed under the same conditions as above.
- a coating without titanium oxide cannot suppress the generation of degraded products generated by uncoated tablets.
- the coating containing titanium oxide A or B was able to suppress the generation of decomposed products generated by uncoated tablets, but generated new decomposed products.
- generation of decomposition products due to “the present compound + light” and “the present compound + titanium oxide + light” could be suppressed.
- the uncoated tablet of Formulation 1 obtained above was coated with the same composition as that of the first coating layer of Formulation 5 so that the coating amount was 0, 1, 3, and 5 mg. Coating was performed with the same composition as the second coating layer of Formulation 5 so that the coating amount was 3 mg. Two-layer coated tablets of Formulations 6, 7, 8, and 9 were obtained.
- the uncoated tablet of Formulation 1 obtained above was coated with the same composition as that of the first coating layer of Formulation 5 so that the coating amount was 3 mg. Coating was carried out with the same composition so that the coating amount was 0, 1, and 5 mg, and two-layer coated tablets of Formulations 10, 11, and 12 were obtained.
- the tablets of Formulations 6 to 13 were irradiated with 1,500,000 Lux ⁇ hr light using a light tester, and an analog test was performed using HPLC. The analog test was performed under the same conditions as above.
- Table 5 shows the test results. When both the first and second coating amounts were 3 mg, generation of decomposed products could be suppressed. Table 5 Test results of related substances after irradiation of 1,500,000 LuXhr
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003516526A JPWO2003011296A1 (ja) | 2001-07-30 | 2002-07-29 | アミノベンゼンスルホン酸誘導体を活性成分とする医薬品製剤 |
KR10-2004-7000363A KR20040020067A (ko) | 2001-07-30 | 2002-07-29 | 아미노벤젠설폰산 유도체를 활성 성분으로 하는 의약품 제제 |
CA002455858A CA2455858A1 (en) | 2001-07-30 | 2002-07-29 | Pharmaceutical preparations containing aminobenzene- sulfonic acid derivatives as the active ingredient |
US10/485,218 US20050004139A1 (en) | 2001-07-30 | 2002-07-29 | Pharmaceutical preparations containing aminobenzene-sulfonic acid derivatives as the active ingredient |
EP02751749A EP1419775A1 (en) | 2001-07-30 | 2002-07-29 | Pharmaceutical preparations containing aminobenzene-sulfonic acid derivatives as the active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-229086 | 2001-07-30 | ||
JP2001229086 | 2001-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003011296A1 true WO2003011296A1 (en) | 2003-02-13 |
Family
ID=19061485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/007656 WO2003011296A1 (en) | 2001-07-30 | 2002-07-29 | Pharmaceutical preparations containing aminobenzene- sulfonic acid derivatives as the active ingredient |
Country Status (7)
Country | Link |
---|---|
US (1) | US20050004139A1 (ja) |
EP (1) | EP1419775A1 (ja) |
JP (1) | JPWO2003011296A1 (ja) |
KR (1) | KR20040020067A (ja) |
CN (1) | CN1638773A (ja) |
CA (1) | CA2455858A1 (ja) |
WO (1) | WO2003011296A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004019946A1 (ja) * | 2002-08-30 | 2004-03-11 | Mitsubishi Pharma Corporation | 細胞内ナトリウムイオン過蓄積抑制薬 |
WO2005084668A1 (ja) * | 2004-03-05 | 2005-09-15 | Mitsubishi Pharma Corporation | 虚血性循環器疾患の予防及び/又は治療のための薬剤 |
WO2005097070A1 (ja) * | 2004-04-08 | 2005-10-20 | Kyowa Hakko Kogyo Co., Ltd. | 安定性の向上した固形製剤およびその製造方法 |
JPWO2004022545A1 (ja) * | 2002-09-06 | 2005-12-22 | 三菱ウェルファーマ株式会社 | 移植臓器保護剤 |
JP2007126407A (ja) * | 2005-11-04 | 2007-05-24 | Towa Yakuhin Kk | アムロジピンを含有する安定化された医薬品組成物 |
WO2008018556A1 (en) * | 2006-08-09 | 2008-02-14 | Mitsubishi Tanabe Pharma Corporation | Tablet |
JP2016128390A (ja) * | 2015-01-09 | 2016-07-14 | ダイト株式会社 | テルミサルタン含有フィルムコート錠 |
JP2020079314A (ja) * | 2015-01-20 | 2020-05-28 | 日本ケミファ株式会社 | ロスバスタチンカルシウム製剤及びレーザー照射によるフィルムコーティング錠の印字方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2564833B1 (en) * | 2008-07-28 | 2017-12-20 | Takeda Pharmaceutical Company Limited | Photostabilized pharmaceutical composition |
CN101975831B (zh) * | 2010-11-25 | 2012-09-05 | 中国检验检疫科学研究院 | 高效液相色谱法测定化妆品中苯酚磺酸锌的方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0390654A1 (en) * | 1989-03-27 | 1990-10-03 | Mitsubishi Chemical Corporation | Aminobenzenesulfonic acid derivative |
JPH04139127A (ja) * | 1990-09-27 | 1992-05-13 | Mitsubishi Kasei Corp | 心疾患を予防または治療する薬剤 |
EP0779283A1 (en) * | 1995-12-15 | 1997-06-18 | Mitsubishi Chemical Corporation | Monohydrates of aminobenzenesulfonic acid derivatives and method for preparation thereof |
JPH10298077A (ja) * | 1997-04-24 | 1998-11-10 | Mitsubishi Chem Corp | 心筋症の治療、予防剤 |
WO1999040919A1 (fr) * | 1998-02-12 | 1999-08-19 | Mitsubishi Chemical Corporation | Medicaments contre les troubles diastoliques cardiaques |
JP2001081033A (ja) * | 1999-09-09 | 2001-03-27 | Towa Yakuhin Kk | 耐光性塩酸エピナスチンフィルムコート錠 |
WO2001045739A1 (fr) * | 1999-12-21 | 2001-06-28 | Mitsubishi Pharma Corporation | Remedes et/ou medicaments preventifs pour troubles du systeme nerveux |
-
2002
- 2002-07-29 JP JP2003516526A patent/JPWO2003011296A1/ja active Pending
- 2002-07-29 CA CA002455858A patent/CA2455858A1/en not_active Abandoned
- 2002-07-29 CN CNA028150279A patent/CN1638773A/zh active Pending
- 2002-07-29 EP EP02751749A patent/EP1419775A1/en not_active Withdrawn
- 2002-07-29 KR KR10-2004-7000363A patent/KR20040020067A/ko not_active Application Discontinuation
- 2002-07-29 WO PCT/JP2002/007656 patent/WO2003011296A1/ja not_active Application Discontinuation
- 2002-07-29 US US10/485,218 patent/US20050004139A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0390654A1 (en) * | 1989-03-27 | 1990-10-03 | Mitsubishi Chemical Corporation | Aminobenzenesulfonic acid derivative |
JPH04139127A (ja) * | 1990-09-27 | 1992-05-13 | Mitsubishi Kasei Corp | 心疾患を予防または治療する薬剤 |
EP0779283A1 (en) * | 1995-12-15 | 1997-06-18 | Mitsubishi Chemical Corporation | Monohydrates of aminobenzenesulfonic acid derivatives and method for preparation thereof |
JPH10298077A (ja) * | 1997-04-24 | 1998-11-10 | Mitsubishi Chem Corp | 心筋症の治療、予防剤 |
WO1999040919A1 (fr) * | 1998-02-12 | 1999-08-19 | Mitsubishi Chemical Corporation | Medicaments contre les troubles diastoliques cardiaques |
JP2001081033A (ja) * | 1999-09-09 | 2001-03-27 | Towa Yakuhin Kk | 耐光性塩酸エピナスチンフィルムコート錠 |
WO2001045739A1 (fr) * | 1999-12-21 | 2001-06-28 | Mitsubishi Pharma Corporation | Remedes et/ou medicaments preventifs pour troubles du systeme nerveux |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004019946A1 (ja) * | 2002-08-30 | 2004-03-11 | Mitsubishi Pharma Corporation | 細胞内ナトリウムイオン過蓄積抑制薬 |
JPWO2004022545A1 (ja) * | 2002-09-06 | 2005-12-22 | 三菱ウェルファーマ株式会社 | 移植臓器保護剤 |
WO2005084668A1 (ja) * | 2004-03-05 | 2005-09-15 | Mitsubishi Pharma Corporation | 虚血性循環器疾患の予防及び/又は治療のための薬剤 |
JP5121229B2 (ja) * | 2004-04-08 | 2013-01-16 | 協和発酵キリン株式会社 | 安定性の向上した固形製剤およびその製造方法 |
JPWO2005097070A1 (ja) * | 2004-04-08 | 2007-08-16 | 協和醗酵工業株式会社 | 安定性の向上した固形製剤およびその製造方法 |
JP2012184267A (ja) * | 2004-04-08 | 2012-09-27 | Kyowa Hakko Kirin Co Ltd | 安定性の向上した固形製剤およびその製造方法 |
WO2005097070A1 (ja) * | 2004-04-08 | 2005-10-20 | Kyowa Hakko Kogyo Co., Ltd. | 安定性の向上した固形製剤およびその製造方法 |
KR101252863B1 (ko) * | 2004-04-08 | 2013-04-09 | 교와 핫꼬 기린 가부시키가이샤 | 안정성이 향상된 고형 제제 및 그 제조 방법 |
JP2007126407A (ja) * | 2005-11-04 | 2007-05-24 | Towa Yakuhin Kk | アムロジピンを含有する安定化された医薬品組成物 |
JP4675751B2 (ja) * | 2005-11-04 | 2011-04-27 | 東和薬品株式会社 | アムロジピンを含有する安定化された医薬品組成物 |
WO2008018556A1 (en) * | 2006-08-09 | 2008-02-14 | Mitsubishi Tanabe Pharma Corporation | Tablet |
JP2016128390A (ja) * | 2015-01-09 | 2016-07-14 | ダイト株式会社 | テルミサルタン含有フィルムコート錠 |
JP2020079314A (ja) * | 2015-01-20 | 2020-05-28 | 日本ケミファ株式会社 | ロスバスタチンカルシウム製剤及びレーザー照射によるフィルムコーティング錠の印字方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1638773A (zh) | 2005-07-13 |
KR20040020067A (ko) | 2004-03-06 |
CA2455858A1 (en) | 2003-02-13 |
JPWO2003011296A1 (ja) | 2004-11-18 |
US20050004139A1 (en) | 2005-01-06 |
EP1419775A1 (en) | 2004-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023062189A (ja) | 癌を処置する方法 | |
US8609706B2 (en) | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | |
US20160324852A1 (en) | Compositions and methods of treating a neurodegenerative disease | |
US12077554B2 (en) | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer | |
JP2018525414A (ja) | 癌を処置するための方法 | |
TW201632511A (zh) | 治療精神分裂症之組成物及方法 | |
WO2003011296A1 (en) | Pharmaceutical preparations containing aminobenzene- sulfonic acid derivatives as the active ingredient | |
JP2009539956A (ja) | 医薬品 | |
TWI345561B (en) | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | |
HU230366B1 (hu) | Kinurénsavamid származékok alkalmazása Huntington-kór kezelésére | |
EP4349341A1 (en) | Pharmaceutical preparation for preventing or treating pulmonary fibrosis | |
WO2023280090A1 (zh) | 一种药用组合物及其制备方法和用途 | |
CN117616022A (zh) | 晶形 | |
US20230172867A1 (en) | A method for treating cancer with an oral dosage form of an fgfr4 inhibitor | |
TW201806601A (zh) | σ受體配體在皰疹後遺疼痛中的用途 | |
ES2262515T3 (es) | R-hidroxinefazodona. | |
TW201511757A (zh) | 多晶型形式 | |
BRPI0707736A2 (pt) | formulaÇÕes de imidazolilalquil-piridinas de dosagem estÁvel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020047000363 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003516526 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2455858 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028150279 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002751749 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002751749 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10485218 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002751749 Country of ref document: EP |